Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis

FRANKLIN LAKES, N.J., Aug. 25, 2015 /PRNewswire/ — BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has completed the acquisition of Cellular Research, Inc. BD is a global leader in characterizing and isolating single cells for analysis, with more than 30 years […]

Read More »

Acorda Therapeutics Shares Surge

A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices. The U.S. Patent and Trademark Office’s review board ruled against Mr. Bass’s challenge of […]

Read More »

China’s Hepalink USA to Buy American Firm Cytovance for $205.68M+

Hepalink USA, the wholly owned U.S. subsidiary of Shenzhen Hepalink Pharmaceutical, will acquire the biopharmaceutical contract development manufacturing organization Cytovance® Biologics for $205.68 million cash plus additional contingent payments, Cytovance said today. The deal adds a CDMO to Hepalink’s U.S. portfolio, which includes Scientific Protein Laboratories (SPL), a global supplier of active pharmaceutical ingredients (APIs). […]

Read More »

Royal DSM to Slash as Many as 1,100 Jobs to Placate Investors

THE HAGUE, Netherlands (AP) — Dutch nutritional supplements and chemicals company Royal DSM NV says it is laying off between 900 and 1,100 staff worldwide as part of a reorganization of its businesses. The company announced the job cuts Tuesday, saying the move would cut costs by 125-150 million euros ($144-173 million) by the end […]

Read More »

Amgen Opens Up $300 Million Facility in Ireland

Biopharmaceutical giant Amgen has opened its new €300m facility in Dun Laoghaire, following a five-year revamp job of the old Pfizer building. The development included the construction of an 11,500sqm production plant and a 5,800sqm cold chain warehouse – there was also significant refurbishment on buildings that already existed onsite, with total employment numbers there […]

Read More »

Gilead: Waiting Is the Best Part

No pain, no gain. Shareholders in Gilead Sciences (GILD 6.78%) may want to repeat that workout mantra as they watch markets slide. True, Gilead has taken some lumps. It was down 2% at one point Monday and is off about 9% over the past five trading days. The Nasdaq Biotechnology Index, meanwhile, is down about […]

Read More »

Hedge fund manager Kyle Bass loses challenges to pharma patents

Prominent hedge fund manager Kyle Bass’s campaign to wipe out certain drug patents hit a roadblock on Monday when the U.S. Patent and Trademark Office declined to formally review two patents on Acorda Therapeutics Inc’s flagship multiple sclerosis drug, Ampyra. The decision to reject a review of the patents’ validity comes as the pharmaceutical industry […]

Read More »

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination Therapy With Standard of Care Oncology Treatments; Transaction Price of $410 Million Upfront, Up to $160 Million in Milestones and Mid-Single Digit Royalties SAN FRANCISCO, […]

Read More »

BioMarin Sells Phase III Breast Cancer Drug to Medivation for $570 Million

San Francisco-based Medivation, Inc. (MDVN), and San Rafael, Calif.-based BioMarin Pharmaceutical Inc. (BMRN) announced today that they have signed a deal for Medivation to buy all worldwide rights to talazoparib, formerly called BMN 673, for breast cancer treatment. Medivation will take over all research, development, regulatory and commercial activities.   Medivation will pay BioMarin $410 […]

Read More »

Google X’s Life Sciences Becomes First Standalone Company Under Alphabet

On Aug. 20, 2015, Google Inc., soon to become Alphabet, announced on its blog that the first company to stand alone under Alphabet will be Google X’s Life Sciences. Writing on the blog, Sergey Brin, Google co-founder, said, “I am delighted to announce that the life sciences team is now ready to graduate from our […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom